Literature DB >> 32504718

Diffuse coronary artery dilation predicted worse long-term outcomes in patients with coronary artery Ectasia.

Zhongxing Cai1, Jianxin Liu1, Haoyu Wang1, Dong Yin1, Weihua Song2, Kefei Dou3.   

Abstract

BACKGROUND: Coronary artery ectasia (CAE) is a rare finding in coronary angiography and associated with worse clinical outcomes. According to the extent of the dilated lesions, CAE is classified into diffuse and focal dilation. The difference in clinical outcomes between these 2 phenotypes remains unknown.
METHODS: A cohort study was conducted comprising CAE patients identified by coronary angiography between January 2009 to December 2013. Follow-up was proceeded annually and the primary outcome was major adverse cardiovascular events (MACE) defined as a component of cardiovascular death and nonfatal myocardial infarction(MI). Kaplan-Meier method and Cox regression models were used to assess the clinical outcomes in diffuse CAE group and focal CAE group. Propensity score matching, propensity score weighting, and subgroup analysis were performed as sensitivity analysis.
RESULTS: A total of 595 patients were included in this study, including 474 individuals with diffuse CAE and 121 with focal CAE. During a median follow-up of 87 months, Patients in diffuse CAE group showed significantly higher incidences of MACE (13.1% vs. 3.3%;HR 4.28, 95%CI 1.56-11.78, P = .005), as well as cardiovascular death (7.0% vs. 1.7%;HR 4.41, 95%CI 1.06-18.39, P = .041). Higher occurrence rate of MACE was consistent in propensity score matched cohort and propensity score weighted analysis. The same trend towards increased risk of MACE in diffuse CAE group was obtained among subgroup analysis.
CONCLUSIONS: Patients with diffuse CAE was associated with increased risk of MACE compared to those with focal CAE. Diffuse dilation found in coronary angiography should receive more attention by physicians.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Aneurysm; Coronary artery ectasia; Major adverse cardiovascular event; Outcome

Mesh:

Year:  2020        PMID: 32504718     DOI: 10.1016/j.ijcard.2020.05.054

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Inflammatory Biomarkers in Coronary Artery Ectasia: A Systematic Review and Meta-Analysis.

Authors:  Dimitrios A Vrachatis; Konstantinos A Papathanasiou; Dimitrios Kazantzis; Jorge Sanz-Sánchez; Sotiria G Giotaki; Konstantinos Raisakis; Andreas Kaoukis; Charalampos Kossyvakis; Gerasimos Deftereos; Bernhard Reimers; Dimitrios Avramides; Gerasimos Siasos; Michael Cleman; George Giannopoulos; Alexandra Lansky; Spyridon Deftereos
Journal:  Diagnostics (Basel)       Date:  2022-04-19

Review 2.  Coronary Artery Ectasia: Review of the Non-Atherosclerotic Molecular and Pathophysiologic Concepts.

Authors:  Gavin H C Richards; Kathryn L Hong; Michael Y Henein; Colm Hanratty; Usama Boles
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

3.  Plasma Big Endothelin-1 Level Predicted 5-Year Major Adverse Cardiovascular Events in Patients With Coronary Artery Ectasia.

Authors:  Zhongxing Cai; Haoyu Wang; Sheng Yuan; Dong Yin; Weihua Song; Kefei Dou
Journal:  Front Cardiovasc Med       Date:  2021-11-29

Review 4.  Treatment and Outcome of Patients With Coronary Artery Ectasia: Current Evidence and Novel Opportunities for an Old Dilemma.

Authors:  Luca Esposito; Marco Di Maio; Angelo Silverio; Francesco Paolo Cancro; Michele Bellino; Tiziana Attisano; Fabio Felice Tarantino; Giovanni Esposito; Carmine Vecchione; Gennaro Galasso; Cesare Baldi
Journal:  Front Cardiovasc Med       Date:  2022-02-04

5.  Development and Validation of a Nomogram for Predicting the Risk of Adverse Cardiovascular Events in Patients with Coronary Artery Ectasia.

Authors:  Zhongxing Cai; Yintang Wang; Luqi Li; Haoyu Wang; Chenxi Song; Dong Yin; Weihua Song; Kefei Dou
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-14

6.  Effect of type 2 diabetes on coronary artery ectasia: smaller lesion diameter and shorter lesion length but similar adverse cardiovascular events.

Authors:  Zhongxing Cai; Luqi Li; Haoyu Wang; Sheng Yuan; Dong Yin; Weihua Song; Kefei Dou
Journal:  Cardiovasc Diabetol       Date:  2022-01-19       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.